基础医学与临床 ›› 2021, Vol. 41 ›› Issue (6): 890-894.

• 临床研究 • 上一篇    下一篇

塞来昔布联合IMRT对老年中晚期非小细胞肺癌患者免疫功能和血清肿瘤标志物的影响

任孟先1, 梁伟2, 刘艳1*   

  1. 1.太和县人民医院 放疗科, 安徽 太和 236600;
    2.安徽医科大学第一附属医院 放疗科,安徽 合肥 230031
  • 收稿日期:2021-01-19 修回日期:2021-04-16 出版日期:2021-06-05 发布日期:2021-05-31
  • 通讯作者: *354368932@qq.com

Effects of celecoxib combined with IMRT on immune function and serum tumor markers in elderly patients with advanced non-small cell lung cancer

REN Meng-xian1, LIANG Wei2, LIU Yan1*   

  1. 1. Department of Radiotherapy, Taihe County People's Hospital, Taihe 236600;
    2. Department of Radiotherapy, the First Affiliated Hospital of Anhui Medical University, Hefei 230031,China
  • Received:2021-01-19 Revised:2021-04-16 Online:2021-06-05 Published:2021-05-31
  • Contact: *354368932@qq.com

摘要: 目的 分析塞来昔布联合调强放疗(IMRT)对非小细胞肺癌(NSCLC)患者免疫功能和血清肿瘤标志物的影响及疗效。方法 选取2017年1月至2019年12月太和县人民医院收治的62例NSCLC患者,随机分成两组;将单纯放疗的30例患者设为对照组,将调强放疗联合塞来昔布治疗的32例患者设为实验组。取两组治疗前、治疗后4周空腹静脉血,检测血清肿瘤标志物糖类抗原50(CA50)、糖类抗原125(CA125)、癌胚抗原(CEA)、鳞状细胞癌相关抗原(SCCAg)及T淋巴细胞亚群(CD3+、CD4+、CD8+),判定两组近期疗效,并采用Kaplan-Meier绘制生存曲线。结果 实验组治疗总有效率54.55%,明显高于对照组的31.82%(P<0.05);治疗后两组血清CA50、CA125、CEA、SCCAg水平均较治疗前明显降低(P<0.05),且实验组较对照组明显降低(P<0.05);治疗后实验组CD3+、CD4+测定值较治疗前明显增高(P<0.05),CD8+测定值较治疗前明显降低(P<0.05),而对照组CD3+、CD4+测定值较治疗前明显降低(P<0.05),CD8+测定值较治疗前明显增高(P<0.05),两组间上述T淋巴细胞亚群比较有明显差异(P<0.05);实验组3年生存率38.64 %明显高于对照组的18.18%(P<0.05)。结论 对老年中晚期NSCLC患者实施塞来昔布联合IMRT治疗,可明显下调血清肿瘤标志物水平,有效增强免疫功能,大大提高治疗有效率及生存率。

关键词: 调强放疗, 非小细胞肺癌, 免疫功能, 血清肿瘤标志物, 生存率

Abstract: Objective To analyze the effect of intensity modulated radiation therapy IMRT(intensity modulated radiation therapy) combined with celecoxib on immune function and serum tumor markers in patients with non-small cell lung cancer(NSCLC). Methods Sixty-two patients with NSCLC in Taihe County People's Hospital from January 2017 to December 2019 were selected and randomly divided into two groups; thirty patients with radiotherapy alone were set as the control group, and thirty-two patients with IMRT combined with celecoxib were set as the experimental group. Fasting venous blood was collected before and 4 weeks after treatment to detect the serum tumor markers, including carbohydrate antigen 50(CA50), carbohydrate antigen 125(CA125), carcinoma-embryonic antigen(CEA), squamous cell carcinoma associated antigen(SccAg) and T lymphocyte subsets(CD3+, CD4+, CD8+) in the two groups. The short-term efficacy of the two groups was evaluated, and the survival curve was drawn by Kaplan Meier. Results The total effective rate of the experimental group was 54.55%, which was significantly higher than that of the control group(31.82%)(P<0.05); after treatment, the serum CA50, CA125, CEA, SCCAg levels of the two groups were significantly lower than those before treatment(P<0.05), and the experimental group was significantly lower than that of the control group(P<0.05); after treatment, the test value of CD3+, CD4+ in the experimental group was significantly higher than those before treatment(P<0.05), and the value of CD8+ was significantly higher than those before treatment. Counting of CD3+ and CD4+ in the control group was significantly lower than that before treatment(P<0.05), but CD8+ counting was significantly higher than at before treatment(P<0.05). There was significant difference in T lymphocyte subsets between the two groups(P<0.05). The 3-year survival rate of the experimental group was 38.64%, which was significantly higher than that of the control group(18.18%)(P<0.05). Conclusions Intensity modulated radiation therapy combined with celecoxib in the treatment of elderly patients with advanced NSCLC significantly reduces the level of serum tumor markers, effectively enhances the immune function, and significantly improves the treatment outcome as well as enhances survival rate.

Key words: intensity modulated radiation therapy, non-small cell lung cancer, immune function, serum tumor markers, survival rate

中图分类号: